AAAAAA
Results: 76-100/305
Authors:
MANZKE O
TESCH H
DIEHL V
BOHLEN H
Citation: O. Manzke et al., SINGLE-STEP PURIFICATION OF BISPECIFIC MONOCLONAL-ANTIBODIES FOR IMMUNOTHERAPEUTIC USE BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, Journal of immunological methods, 208(1), 1997, pp. 65-73
Authors:
DIEHL V
HIDDEMANN W
Citation: V. Diehl et W. Hiddemann, LYMPHOMAS, Der Internist, 38(2), 1997, pp. 105-107
Authors:
ENGERT A
SCHNELL R
BARTH S
DIEHL V
Citation: A. Engert et al., IMMUNOTHERAPEUTIC STRATEGIES IN LYMPHOMAS, Der Internist, 38(2), 1997, pp. 150-156
Authors:
BARTH S
WINKLER U
DIEHL V
ENGERT A
Citation: S. Barth et al., IMMUNOTOXINS - ACTIVITY AND USE IN MALIGN ANT DISEASES, Der Internist, 38(11), 1997, pp. 1063-1069
Authors:
HOMBACH A
HEUSER C
SIRCAR R
TILLMANN T
DIEHL V
KRUIS W
POHL C
ABKEN H
Citation: A. Hombach et al., T-CELL TARGETING OF TAG72-CELLS BY A CHIMERIC RECEPTOR WITH ANTIBODY-LIKE SPECIFICITY FOR A CARBOHYDRATE EPITOPE( TUMOR), Gastroenterology, 113(4), 1997, pp. 1163-1170
Authors:
POHL C
HEUSER C
SIRCAR R
TILLMANN T
ZIEGENHAGEN DJ
DIEHL V
KRUIS W
ABKEN H
HOMBACH A
Citation: C. Pohl et al., EXPRESSION OF A CHIMERIC T-CELL RECEPTOR WITH ANTIBODY LIKE SPECIFICITY RESULTS IN CYTOTOXIC T-CELLS WITH SPECIFICITY FOR CA72-4-CELL( TUMOR), Gastroenterology, 112(4), 1997, pp. 640-640
Authors:
HOMBACH A
TILLMANN T
JENSEN M
HEUSER C
SIRCAR R
DIEHL V
KRUIS W
POHL C
Citation: A. Hombach et al., SPECIFIC ACTIVATION OF RESTING T-CELLS AGAINST TUMOR-CELLS BY BISPECIFIC ANTIBODIES AND CD28-MEDIATED COSTIMULATION IS ACCOMPANIED BY TH1 DIFFERENTIATION AND RECRUITMENT OF MHC-INDEPENDENT CYTOTOXICITY, Clinical and experimental immunology, 108(2), 1997, pp. 352-357
Authors:
BOHLEN H
MANZKE O
TITZER S
LORENZEN J
KUBE D
ENGERT A
ABKEN H
WOLF J
DIEHL V
TESCH H
Citation: H. Bohlen et al., PREVENTION OF EPSTEIN-BARR-VIRUS-INDUCED HUMAN B-CELL LYMPHOMA IN SEVERE COMBINED IMMUNODEFICIENT MICE TREATED WITH CD3XCD19 BISPECIFIC ANTIBODIES, CD28 MONOSPECIFIC ANTIBODIES, AND AUTOLOGOUS T-CELLS, Cancer research, 57(9), 1997, pp. 1704-1709
Authors:
KVASNICKA HM
THIELE J
WERDEN C
ZANKOVICH R
DIEHL V
FISCHER R
Citation: Hm. Kvasnicka et al., PROGNOSTIC FACTORS IN IDIOPATHIC (PRIMARY) OSTEOMYELOFIBROSIS, Cancer, 80(4), 1997, pp. 708-719
Authors:
WINKLER U
RIEDER H
MARZ W
VOLIOTIS D
FRANZEN C
SCHMITZ S
REHDER H
DIEHL V
ENGERT A
Citation: U. Winkler et al., ESTABLISHMENT OF A HUMAN MYELOID CELL-LINE FROM THE FIRST PATIENT WITH ROTHMUND-THOMSON-SYNDROME AND ACUTE MYELOID-LEUKEMIA, Blood, 90(10), 1997, pp. 3800-3800
Authors:
VOLIOTIS DL
SCHMITZ S
STAIB P
VONBERGWELTBAILDON M
TESCH H
DIEHL V
Citation: Dl. Voliotis et al., TREATMENT OF POOR-PROGNOSIS ACUTE MYELOID-LEUKEMIA USING IMMUNOTHERAPY WITH INTERLEUKIN-2, Blood, 90(10), 1997, pp. 3857-3857
Authors:
JOX A
ZANDER T
KORNACKER M
FONATSCH C
DIEHL V
WOLF J
Citation: A. Jox et al., ALLELIC LOSS OF CHROMOSOMAL REGIONS IN 6P, 9Q AND 17P IN THE HODGKIN-REED-STERNBERG CELL-DERIVED CELL-LINE L1236, Blood, 90(10), 1997, pp. 3907-3907
Authors:
JOX A
ZANDER T
KORNACKER M
KANZLER H
KUPPERS R
DIEHL V
WOLF J
Citation: A. Jox et al., CLONAL RELAPSE IN HODGKINS-DISEASE, MIXED CELLULARITY SUBTYPE, Blood, 90(10), 1997, pp. 3908-3908
Authors:
JOX A
ZANDER T
BOHLEN H
KANZLER H
KUPPERS R
KORNACKER M
DIEHL V
WOLF J
Citation: A. Jox et al., THE EXPRESSION OF REARRANGED IG GENES IN THE HODGKIN-REED-STERNBERG DERIVED CELL-LINE L1236 IS PREVENTED DUE TO SOMATIC MUTATIONS WITHIN THEIR UNTRANSLATED REGIONS, Blood, 90(10), 1997, pp. 3909-3909
Authors:
KORNACKER M
VOCKERODT M
KUBE D
JOX A
TESCH H
DIEHL V
WOLF J
Citation: M. Kornacker et al., DETECTION OF A HODGKIN-REED-STERNBERG CELL-SPECIFIC IMMUNOGLOBULIN GENE REARRANGEMENT IN THE SERUM DNA OF A PATIENT WITH HODGKINS-DISEASE, Blood, 90(10), 1997, pp. 3914-3914
Authors:
KORNACKER M
SCHLATTNER U
WALLIMANN T
JOX A
DIEHL V
WOLF N
Citation: M. Kornacker et al., EXPRESSION OF CREATINE-KINASE ISOZYMES IN HODGKINS DERIVED CELL-LINES, Blood, 90(10), 1997, pp. 3915-3915
Authors:
LIEBERZ D
SEXTRO M
TESCH H
PAULUS U
DIEHL V
Citation: D. Lieberz et al., IS LIVER-BIOPSY FOR THE STAGING OF HODGKINS LYMPHOMA STILL INDICATED, Blood, 90(10), 1997, pp. 3923-3923
Authors:
RUFFER U
FLECHTNER H
HAMMERSTEIN O
SIEBER M
DIEHL V
Citation: U. Ruffer et al., LONGITUDINAL ASSESSMENT OF THE QUALITY-OF-LIFE (QOL) IN PATIENTS WITHHODGKINS-DISEASE TREATED IN THE HD-8 TRIAL OF THE GERMAN HODGKIN STUDY-GROUP (GHSG), Blood, 90(10), 1997, pp. 3950-3950
Authors:
TESCH H
FRANKLIN J
MACLENNAN K
GEORGII A
DIEHL V
Citation: H. Tesch et al., INDEPENDENT PROGNOSTIC VALUE OF HISTOPATHOLOGIC GRADING OF NODULAR SCLEROSIS HODGKINS-DISEASE IN PATIENTS TREATED WITH MODERN COMBINED-MODALITY THERAPY, Blood, 90(10), 1997, pp. 3959-3959
Authors:
WOLF J
TOPELT K
JOX A
MUCKE S
POLLACK A
BORNKAMM G
DIEHL V
Citation: J. Wolf et al., IN-VIVO TRANSFECTION OF BURKITTS-LYMPHOMA CELLS USING AN EBV-DERIVED EPISOMAL DNA VECTOR, Blood, 90(10), 1997, pp. 4638-4638
Authors:
SCHMITZ N
SEXTRO M
HASENCLEVER D
CARELLA A
FIEDLER F
SCHLIMOK G
HOSSFELD DK
DIEHL V
Citation: N. Schmitz et al., HD-R1 - FIRST RESULTS OF A RANDOMIZED TRIAL COMPARING AGGRESSIVE CHEMOTHERAPY WITH HIGH-DOSE THERAPY (HDT) AND HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH CHEMOSENSITIVE RELAPSE OF HODGKINS-DISEASE (HD), Blood, 90(10), 1997, pp. 499-499
Authors:
MANSMANN G
HUBEL K
SCHAFER H
OBERHAUSER F
WASSMER G
DIEHL V
ENGERT A
Citation: G. Mansmann et al., INCREASE OF ANTIINFLAMMATORY CYTOKINES AND REDUCTION OF POSTOPERATIVEINFECTIONS BY PERIOPERATIVE TREATMENT WITH GRANULOCYTE-COLONY-STIMULATING FACTOR OF PATIENTS WITH ESOPHAGEAL CANCER, Blood, 90(10), 1997, pp. 764-764
Authors:
KORNACKER M
LOFTIN U
MAERZ W
KALLE CV
JOX A
TRUEMPER L
DIEHL V
WOLF J
Citation: M. Kornacker et al., ISOLATION OF GENES PREFERENTIALLY TRANSCRIBED IN PRIMARY HODGKIN-REED-STERNBERG CELLS, Blood, 90(10), 1997, pp. 1494-1494
Authors:
DIEHL V
LATHAN B
ENGERT A
FRANKLIN J
RUFFER U
SIEBER M
WOLF J
PFREUNDSCHUH M
KOCH P
ADLER M
MULLER U
SCHALK P
DOLKEN G
WORST P
BOISSEVAIN F
LOFFLER M
TESCH H
Citation: V. Diehl et al., INTERIM ANALYSIS OF THE HD9 STUDY OF THE GERMAN-HODGKIN-STUDY-GROUP (GHSG) - BEACOPP IS MORE EFFECTIVE THAN COPP-ABVD IN ADVANCED-STAGE HODGKINS-DISEASE, Blood, 90(10), 1997, pp. 1512-1512
Authors:
TESCH H
SANTORO A
FIEDLER F
BONADONNA G
BREDENFELD K
OLIVA C
BUKSMAUI S
SIEBER M
DIEHL V
Citation: H. Tesch et al., PHASE-II STUDY OF GEMCITABINE IN PRETREATED HODGKINS-DISEASE RESULTS OF A MULTICENTER STUDY, Blood, 90(10), 1997, pp. 1514-1514